|
[1]
|
Mirabello, L., Troisi, R.J. and Savage, S.A. (2009) Osteosarcoma Incidence and Survival Rates from 1973 to 2004: Data from the Surveillance, Epidemiology, and End Results Program. Cancer, 115, 1531-1543. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Wang, Y., Zhang, Y., Yang, T., et al. (2017) Long Non-Coding RNA MALAT1 for Promoting Metastasis and Proliferation by Acting as a ceRNA of miR-144-3p in Osteosarcoma Cells. Oncotarget, 31, 59417-59434. [Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
Zhang, C.L., Zhu, K.P., Shen, G.Q., et al. (2016) A Long Non-Coding RNA Contributes to Doxorubicin Resistance of Osteosarcoma. Tumor Biology, 37, 2737-2748. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Harrison, D.J., Geller, D.S., Gill, J.D., et al. (2018) Current and Future Therapeutic Approaches for Osteosarcoma. Expert Review of Anticancer Therapy, 18, 39-50. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Ferrari, S. and Palmerini, E. (2007) Adjuvant and Neoadjuvant Combination Chemotherapy for Osteogenic Sarcoma. Current Opinion in Oncology, 19, 341-346. [Google Scholar] [CrossRef]
|
|
[6]
|
Arndt, C.A., Rose, P.S., Folpe, A.L., et al. (2012) Common Musculoskeletal Tumors of Childhood and Adolescence. Mayo Clinic Proceedings, 87, 475-487. [Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Link, M.P., Goorin, A.M., Miser, A.W., et al. (1986) The Effect of Adjuvant Chemotherapy on Relapse-Free Survival in Patients with Osteosarcoma of the Extremity. New England Journal of Medicine, 314, 1600-1606. [Google Scholar] [CrossRef]
|
|
[8]
|
Meyers, P.A., Schwartz, C.L., Krailo, M.D., et al. (2008) Osteosarcoma: The Addition of Muramyl Tripeptide to Chemotherapy Improves Overall Survival—A Report from the Children’s Oncology Group. Journal of Clinical Oncology, 1, 633-638. [Google Scholar] [CrossRef]
|
|
[9]
|
Longhi, A., Ferrari, S., Bacci, G., et al. (2007) Long-Term Follow-Up of Patients with Doxorubicin-Induced Cardiac Toxicity after Chemotherapy for Osteosarcoma. Anticancer Drugs, 18, 737-744. [Google Scholar] [CrossRef]
|
|
[10]
|
Biermann, J.S., Chow, W., Reed, D.R., et al. (2017) NCCN Guidelines Insights: Bone Cancer, Version 2.2017. Journal of the National Comprehensive Cancer Network, 15, 155-167. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
Chao, C., Xu, L., Bhatia, S., et al. (2016) Cardiovascular Disease Risk Profiles in Survivors of Adolescent and Young Adult (AYA) Cancer: The Kaiser Permanente AYA Cancer Survivors Study. Journal of Clinical Oncology, 34, 1626-1633. [Google Scholar] [CrossRef]
|
|
[12]
|
Lipshultz, S.E., Franco, V.I., Miller, T.L., et al. (2015) Cardiovascular Disease in Adult Survivors of Childhood Cancer. Annual Review of Medicine, 66, 161-176. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Wouters, K.A., Kremer, L.C., Miller, T.L., et al. (2005) Protecting against Anthracycline-Induced Myocardial Damage: A Review of the Most Promising Strategies. British Journal of Haematology, 131, 561-578. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Ganame, J., Claus, P., Uyttebroeck, A., et al. (2007) Myocardial Dysfunction Late after Low-Dose Anthracycline Treatment in Asymptomatic Pediatric Patients. Journal of the American Society of Echocardiography, 20, 135l-1358. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Jones, L.W., Haykowsky, M.J., Swartz, J.J., et al. (2007) Early Breast Cancer Therapy and Cardiovascular Injury. Journal of the American College of Cardiology, 50, 1435-1441. [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
Carver, J.R., Szalda, D. and Ky, B. (2013) Asymptomatic Cardiac Toxicity in Long-Term Cancer Survivors: Defining the Population and Recommendations for Surveillance. Seminars in Oncology, 40, 229-238. [Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
Volkova, M. and Russell, R. (2011) Anthracycline Cardiotoxicity: Prevalence, Pathogenesis and Treatment. Current Cardiology Reviews, 7, 214-220. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
Hengel, C.L., Russell, P.A., Gould, P.A., et al. (2006) Subacute Anthracycline Cardiotoxicity. Heart, Lung and Circulation, 15, 59-61. [Google Scholar] [CrossRef] [PubMed]
|
|
[19]
|
Lindsey, M.L., Lange, R.A., Parsons, H., et al. (2014) The Tell-Tale Heart: Molecular and Cellular Responses to Childhood Anthracycline Exposure. American Journal of Physiology: Heart and Circulatory Physiology, 307, 1379-1389. [Google Scholar] [CrossRef] [PubMed]
|
|
[20]
|
Chatterjee, K., Zhang, J., Honbo, N., et al. (2010) Doxorubicin Cardiomyopathy. Cardiology, 115, 155-162. [Google Scholar] [CrossRef] [PubMed]
|
|
[21]
|
Gilliam, L.A., Moylan, J.S., Patterson, E.W., et al. (2012) Doxorubicin Acts via Mitochondrial ROS to Stimulate Catabolism in C2C12 Myotubes. American Journal of Physiology-Cell Physiology, 302, 195-202. [Google Scholar] [CrossRef] [PubMed]
|
|
[22]
|
Damiani, R.M., Moura, D.J., Viau, C.M., et al. (2016) Pathways of Cardiac Toxicity: Comparison between Chemotherapeutic Drugs Doxoru-Bicin and Mitoxantrone. Archives of Toxicology, 90, 2063-2076. [Google Scholar] [CrossRef] [PubMed]
|
|
[23]
|
Cascales, A., Sánchez-Vega, B., Navarro, N., et al. (2012) Clinical and Genetic Determinants of Anthracycline-Induced Cardiac Iron Accumulation. International Journal of Cardiology, 154, 282-286. [Google Scholar] [CrossRef] [PubMed]
|
|
[24]
|
Koleini, N. and Kardami, E. (2017) Autophagy and Mitophagy in the Context of Doxorubicin-Induced Cardiotoxicity. Oncotarget, 8, 46663-46680. [Google Scholar] [CrossRef] [PubMed]
|
|
[25]
|
Oun, R. and Rowan, E. (2017) Cisplatin Induced Arrhythmia; Electrolyte Imbalance or Disturbance of the SA Node? European Journal of Pharmacology, 15, 125-128. [Google Scholar] [CrossRef] [PubMed]
|
|
[26]
|
Patane, S. (2014) Cardiotoxicity: Cisplatin and Long-Term Cancer Survivors. International Journal of Cardiology, 175, 201-202. [Google Scholar] [CrossRef] [PubMed]
|
|
[27]
|
El-Awady, el-S.E., Moustafa, Y.M., Abo-Elmatty, D.M., et al. (2011) Cisplatin-Induced Cardiotoxicity: Mechanisms and Cardioprotective Strategies. European Journal of Pharmacology, 650, 335-341. [Google Scholar] [CrossRef] [PubMed]
|
|
[28]
|
Trippett, T.M., Schwartz, C.L., Guillerman, R.P., et al. (2015) Ifosfamide and Vinorelbine Is an Effective Reinduction Regimen in Children with Refractory/Relapsed Hodgkin Lymphoma, AHOD00P1: A Children’s Oncology Group Report. Pediatric Blood & Cancer, 62, 60-64. [Google Scholar] [CrossRef] [PubMed]
|
|
[29]
|
Cardinale, D., Bacchiani, G., Beggiato, M., et al. (2013) Strategies to Prevent and Treat Cardiovascular Risk in Cancer Patients. Seminars in Oncology, 40, 186-198. [Google Scholar] [CrossRef] [PubMed]
|
|
[30]
|
Curigliano, G., Cardinale, D., Dent, S., et al. (2016) Cardiotoxicity of Anticancer Treatments: Epidemiology, Detection, and Management. CA: A Cancer Journal for Clinicians, 66, 309-325. [Google Scholar] [CrossRef] [PubMed]
|
|
[31]
|
Thavendiranathan, P., Poulin, F., Lim, K.D., et al. (2014) Use of Myocardial Strain Imaging by Echocardiography for the Early Detection of Cardiotoxicity in Patients during and after Cancer Chemotherapy: A Systematic Review. Journal of the American College of Cardiology, 63, 2751-2768. [Google Scholar] [CrossRef] [PubMed]
|
|
[32]
|
Cardinale, D., Salvatici, M. and Sandri, M.T. (2011) Role of Biomarkers in Cardioncology. Clinical Chemistry and Laboratory Medicine, 49, 1937-1948. [Google Scholar] [CrossRef]
|
|
[33]
|
Christenson, E.S., James, T., Agrawal, V., et al. (2015) Use of Biomarkers for the Assessment of Chemotherapy-Induced Cardiac Toxicity. Clinical Biochemistry, 48, 223-235. [Google Scholar] [CrossRef] [PubMed]
|
|
[34]
|
Hochster, H.S. (1998) Clinical Pharmacology of Dexrazoxane. Seminars in Oncology, 25, 37-42.
|
|
[35]
|
Lipshultz, S.E., Cochran, T.R., Franco, V.I., et al. (2013) Treatment-Related Cardiotoxicity in Survivors of Childhood Cancer. Nature Reviews Clinical Oncology, 10, 697-710. [Google Scholar] [CrossRef] [PubMed]
|
|
[36]
|
Vijay, V., Moland, C.L., Han, T., et al. (2016) Early Transcriptional Changes in Cardiac Mitochondria during Chronic Doxorubicin Exposure and Mitigation by Dexrazoxane in Mice. Toxicology and Applied Pharmacology, 295, 68-84. [Google Scholar] [CrossRef] [PubMed]
|
|
[37]
|
Hasinoff, B.B., Patel, D. and Wu, X. (2017) Molecular Mechanisms of the Cardiotoxicity of the Proteasomal-Targeted Drugs Bortezomib and Carfilzomib. Cardiovascular Toxicology, 17, 237-250. [Google Scholar] [CrossRef] [PubMed]
|
|
[38]
|
Ebb, D., Meyers, P., Grier, H., et al. (2012) Phase II Trial of Trastuzumab in Combination with Cytotoxic Chemotherapy for Treatment of Metastatic Osteosarcoma with Human Epidermal Growth Factor Receptor 2 Overexpression: A Report from the Children’s Oncology Group. Journal of Clinical Oncology, 30, 2545-2551. [Google Scholar] [CrossRef]
|
|
[39]
|
Schwartz, C.L., Wexler, L.H., Krailo, M.D., et al. (2016) Intensified Chemotherapy with Dexrazoxane Cardioprotection in Newly Diagnosed Nonmetastatic Osteosarcoma: A Report from the Children’s Oncology Group. Pediatric Blood & Cancer, 63, 54-61. [Google Scholar] [CrossRef] [PubMed]
|
|
[40]
|
Lipshultz, S.E., Lipsitz, S.R., Sallan, S.E., et al. (2002). Long-Term Enalapril Therapy for Left Ventricular Dysfunction in Doxorubicin-Treated Survivors of Childhood Cancer. Journal of Clinical Oncology, 1, 4517-4522.[CrossRef]
|
|
[41]
|
Tamene, A.M., Masri, C. and Konety, S.H. (2015) Cardiovascular MR Imaging in Cardio-Oncology. Magnetic Resonance Imaging Clinics of North America, 23, 105-116. [Google Scholar] [CrossRef] [PubMed]
|